Laduviglusib (CHIR-99021)

Catalog No.S1263 Batch:S126310

Technical Data

Formula

C₂₂H₁₈Cl₂N₈

Molecular Weight

465.34

CAS No.

252917-06-9

Solubility (25°C)*

In vitro

DMSO

93 mg/mL (199.85 mM)

Water

Insoluble

Ethanol

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution

5%DMSO 1 Corn oil

0.65mg/ml

Taking the 1 mL working solution as an example, add 50 μL of 13 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Laduviglusib (CHIR-99021, CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.

Targets

GSK-3β ^[1] (Cell-free assay)	GSK-3α ^[1] (Cell-free assay)
6.7 nM	10 nM

In vitro

CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, CHIR-99021 shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. CHIR-99021 induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM^[1].

In vivo

Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Oral administration of CHIR-99021 at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively, and the higher dose of CHIR-99021 also reduces hyperglycemia before the oral glucose challenge^[1].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines Insulin receptor–expressing CHO-IR cells; Primary rat hepatocytes Concentrations 0.01-10 μM Incubation Time 30 min Method CHO-IR cells expressing human insulin receptor are grown to 80% confluence in Hamm’s F12 medium with 10% fetal bovine serum and without hypoxanthine. Trypsinized cells are seeded in 6-well plates at 1 × 106 cells/well in 2 ml of medium without fetal bovine serum. After 24 h, medium is replaced with 1 ml of serum-free medium containing GSK-3 inhibitor or control (final DMSO concentration <0.1%) for 30 min at 37°C. Cells are lysed and centrifuged 15 min at 4°C/14000g. The activity ratio of GS is calculated as the GS activity in the absence of glucose-6-phosphate divided by the activity in the presence of 5 mmol/l glucose-6-phosphate, using the filter paper assay of Thomas et al.
Animal Study:^{^[1]}	Animal Models Female db/db mice; Male ZDF rats Dosages 8-48 mg/kg Administration oral administration

Cell Assay:^{^[1]}

Cell lines
Insulin receptor–expressing CHO-IR cells; Primary rat hepatocytes
Concentrations
0.01-10 μM
Incubation Time
30 min
Method
CHO-IR cells expressing human insulin receptor are grown to 80% confluence in Hamm’s F12 medium with 10% fetal bovine serum and without hypoxanthine. Trypsinized cells are seeded in 6-well plates at 1 × 106 cells/well in 2 ml of medium without fetal bovine serum. After 24 h, medium is replaced with 1 ml of serum-free medium containing GSK-3 inhibitor or control (final DMSO concentration <0.1%) for 30 min at 37°C. Cells are lysed and centrifuged 15 min at 4°C/14000g. The activity ratio of GS is calculated as the GS activity in the absence of glucose-6-phosphate divided by the activity in the presence of 5 mmol/l glucose-6-phosphate, using the filter paper assay of Thomas et al.

Animal Study:^{^[1]}

Animal Models
Female db/db mice; Male ZDF rats
Dosages
8-48 mg/kg
Administration
oral administration

References

[1] Ring DB, et al. Diabetes. 2003, 52(3):588-595.

Customer Product Validation

: , , Dr. Yong-Weon Yi from Georgetown University Medical Center

: Data from [Data independently produced by , , Med Oncol, 2017, 35(1):7]

Selleck's Laduviglusib (CHIR-99021) has been cited by 909 publications

Lung endothelium exploits susceptible tumor cell states to instruct metastatic latency [ Nat Cancer, 2024, 10.1038/s43018-023-00716-7]	PubMed: 38308117
Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity [ Circ Res, 2024, 134(5):482-501]	PubMed: 38323474
Decellularized heart extracellular matrix alleviates activation of hiPSC-derived cardiac fibroblasts [ Bioact Mater, 2024, 31:463-474]	PubMed: 37701451
Nongenetic Optical Modulation of Pluripotent Stem Cells Derived Cardiomyocytes Function in the Red Spectral Range [ Adv Sci (Weinh), 2024, 11(3):e2304303]	PubMed: 37948328
Biosafe cerium oxide nanozymes protect human pluripotent stem cells and cardiomyocytes from oxidative stress [ J Nanobiotechnology, 2024, 22(1):132]	PubMed: 38532378
Developmental role of macrophages modeled in human pluripotent stem cell-derived intestinal tissue [ Cell Rep, 2024, 43(1):113616]	PubMed: 38150367
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids [ Oncogene, 2024, 43(3):155-170]	PubMed: 37985676
Kupffer cells abrogate homing and repopulation of allogeneic hepatic progenitors in injured liver site [ Stem Cell Res Ther, 2024, 15(1):48]	PubMed: 38378583
Critical contribution of mitochondria in the development of cardiomyopathy linked to desmin mutation [ Stem Cell Res Ther, 2024, 15(1):10]	PubMed: 38167524
HAND factors regulate cardiac lineage commitment and differentiation from human pluripotent stem cells [ Stem Cell Res Ther, 2024, 15(1):31]	PubMed: 38317221

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.